Autism care pathway in Europe.


Journal

European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820

Informations de publication

Date de publication:
11 09 2023
Historique:
medline: 23 10 2023
pubmed: 11 9 2023
entrez: 11 9 2023
Statut: epublish

Résumé

Autism is a lifelong complex neurodevelopmental condition that affects brain development and behaviour with significant consequences for everyday life. Despite its personal, familial, and societal impact, Europe-wide harmonised guidelines are still lacking for early detection, diagnosis, and intervention, leading to an overall unsatisfactory autistic person and carer journey. The care pathway for autistic children and adolescents was analysed in Italy, Spain and the UK from the perspective of carers (using a survey aimed at caregivers of autistic children 0-18 years old), the autistic community, and professionals in order to identify major barriers (treatment gaps) preventing carers from receiving information, support, and timely screening/diagnosis and intervention. Across all three countries, analysis of the current care pathway showed: long waits from the time carers raised their first concerns about a child's development and/or behaviour until screening and confirmed diagnosis; delayed or no access to intervention once a diagnosis was confirmed; limited information about autism and how to access early detection services; and deficient support for families throughout the journey. These findings call for policy harmonisation in Europe to shorten long wait times for diagnosis and intervention and therefore, improve autistic people and their families' journey experience and quality of life.

Sections du résumé

BACKGROUND
Autism is a lifelong complex neurodevelopmental condition that affects brain development and behaviour with significant consequences for everyday life. Despite its personal, familial, and societal impact, Europe-wide harmonised guidelines are still lacking for early detection, diagnosis, and intervention, leading to an overall unsatisfactory autistic person and carer journey.
METHODS
The care pathway for autistic children and adolescents was analysed in Italy, Spain and the UK from the perspective of carers (using a survey aimed at caregivers of autistic children 0-18 years old), the autistic community, and professionals in order to identify major barriers (treatment gaps) preventing carers from receiving information, support, and timely screening/diagnosis and intervention.
RESULTS
Across all three countries, analysis of the current care pathway showed: long waits from the time carers raised their first concerns about a child's development and/or behaviour until screening and confirmed diagnosis; delayed or no access to intervention once a diagnosis was confirmed; limited information about autism and how to access early detection services; and deficient support for families throughout the journey.
CONCLUSIONS
These findings call for policy harmonisation in Europe to shorten long wait times for diagnosis and intervention and therefore, improve autistic people and their families' journey experience and quality of life.

Identifiants

pubmed: 37694810
doi: 10.1192/j.eurpsy.2023.2435
pii: S0924933823024355
pmc: PMC10594203
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e81

Références

J Pediatr. 2015 Jun;166(6):1431-9.e1
pubmed: 25888348
BMJ Open. 2013 Jun 20;3(6):
pubmed: 23788511
Rev Prat. 2019 Sep;69(7):738-742
pubmed: 32233312
Am J Intellect Dev Disabil. 2017 Jan;122(1):49-61
pubmed: 28095057
J Autism Dev Disord. 2017 Aug;47(8):2314-2325
pubmed: 28480480
Pediatrics. 2007 Nov;120(5):1162-82
pubmed: 17967921
Am J Ment Retard. 2007 Nov;112(6):450-61
pubmed: 17963436
Brain Sci. 2017 Dec 01;7(12):
pubmed: 29194420
J Fam Theory Rev. 2013 Sep;5(3):194-213
pubmed: 24795780
J Autism Dev Disord. 2020 Sep;50(9):3380-3394
pubmed: 31606886
Autism. 2014 Oct;18(7):756-70
pubmed: 24789871
PLoS One. 2018 Aug 30;13(8):e0202336
pubmed: 30161146
JAMA Pediatr. 2014 Aug;168(8):721-8
pubmed: 24911948
Eur Psychiatry. 2018 Sep;53:107-115
pubmed: 30036773
J Child Psychol Psychiatry. 2004 Feb;45(2):212-29
pubmed: 14982237
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Autism Dev Disord. 2018 Nov;48(11):3761-3772
pubmed: 29948530
Autism. 2009 May;13(3):317-36
pubmed: 19369391
J Child Psychol Psychiatry. 2019 Dec;60(12):1353-1356
pubmed: 31595973
Br J Psychiatry. 2009 Jun;194(6):500-9
pubmed: 19478287
Eur Psychiatry. 2014 Jan;29(1):11-9
pubmed: 24275633
Lancet. 2022 Jan 15;399(10321):271-334
pubmed: 34883054
Autism Res. 2012 Jun;5(3):160-79
pubmed: 22495912
Autism. 2015 Aug;19(6):673-83
pubmed: 25073749
Autism. 2015 Feb;19(2):158-67
pubmed: 24443331
Autism. 2022 Nov;26(8):2136-2150
pubmed: 35261293
Lancet. 2006 Jul 15;368(9531):210-5
pubmed: 16844490

Auteurs

Maria A Mendez (MA)

Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
CIBERSAM (Mental Health Networking Biomedical Research Centre), Madrid, Spain.

Bethany Oakley (B)

Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
AIMS-2-TRIALS consortium.

Roberto Canitano (R)

Azienda ospedaliero-universitaria Senese, Siena, Italy.

Antonia San José-Cáceres (A)

Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
CIBERSAM (Mental Health Networking Biomedical Research Centre), Madrid, Spain.
AIMS-2-TRIALS consortium.

Michela Tinelli (M)

Department of Health Policy, London School of Economics and Political Science, London, UK.

Martin Knapp (M)

Department of Health Policy, London School of Economics and Political Science, London, UK.

James Cusack (J)

Autistica, London, UK.

Mara Parellada (M)

Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
CIBERSAM (Mental Health Networking Biomedical Research Centre), Madrid, Spain.
AIMS-2-TRIALS consortium.
Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
School of Medicine, Universidad Complutense, Madrid, Spain.

Ricardo Canal-Bedia (R)

Universidad de Salamanca, Salamanca, Spain.

Alvaro Bejarano-Martin (A)

Universidad de Salamanca, Salamanca, Spain.

Declan G M Murphy (DGM)

Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
AIMS-2-TRIALS consortium.

Vinciane Quoidbach (V)

European Brain Council, Brussels, Belgium.

Celso Arango (C)

Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
CIBERSAM (Mental Health Networking Biomedical Research Centre), Madrid, Spain.
AIMS-2-TRIALS consortium.
Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
School of Medicine, Universidad Complutense, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH